Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:16:15 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:INCY - INCYTE CORPORATION - https://www.incyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INCY - Q1.0101.00·108.202.5108.39+5.635.52,193.9233,42229,731103.75  108.52  103.52112.29  53.5619:47:00Jan 2715 min RT 2¢

Recent Trades - Last 10 of 29731
Time ETExPriceChangeVolume
19:47:00Q108.395.631
19:26:13Q107.915.15190
18:35:31Q108.295.531
18:35:31Q108.295.539
18:35:13Q106.00013.24011
18:35:11Q108.305.541
18:11:53Q108.385.621
18:11:45Q108.01115.251180
18:11:20Q108.385.6250
17:56:25Q108.255.49464

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-27 08:00U:INCYNews ReleaseIncyte to Report Fourth Quarter and Year-End 2025 Financial Results
2026-01-05 07:30U:INCYNews ReleaseIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(TM)/Minjuvi(TM)) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
2025-12-22 02:44U:INCYNews ReleaseIncyte Japan Announces Approval of Minjuvi(TM) (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-12-22 02:42U:INCYNews ReleaseIncyte Japan Announces Approval of Zynyz(TM) (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
2025-12-18 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2025-12-17 11:20U:INCYNews ReleaseIncyte Announces European Commission Approval of Minjuvi(TM) (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-12-12 08:30U:INCYNews ReleaseIncyte Announces Change to its Board of Directors
2025-12-08 16:30U:INCYNews ReleaseIncyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
2025-12-07 09:30U:INCYNews ReleaseIncyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
2025-12-07 09:30U:INCYNews ReleaseIncyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
2025-12-03 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-12-02 09:15U:INCYNews ReleaseIncyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
2025-12-01 08:00U:INCYNews ReleaseIncyte Appoints Richard Hoffman as Executive Vice President and General Counsel
2025-11-19 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2025-11-06 09:15U:INCYNews ReleaseIncyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
2025-11-04 07:01U:INCYNews ReleasePrelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
2025-11-03 09:31U:INCYNews ReleaseIncyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
2025-10-30 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2025-10-28 07:00U:INCYNews ReleaseIncyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-10-27 07:30U:INCYNews ReleaseIncyte and Enable Injections Announce Strategic Partnership for enFuse(TM) On-Body Delivery System